Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Apomorphine Hydrochloride (CAS 314-19-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added ...

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...

- The first and only sublingual therapy for the on-demand treatment of OFF episodes in patients with Parkinson’s disease is now available in the United States - MARLBOROUGH, Mass.--(BUSINESS ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in ...

TruPharma and its development and commercial partner Sage have received the Food and Drug Administration’s blessing for generic apomorphine hydrochloride cartridges 30 mg/3 mL (10 mg/mL). The ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous infusion ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease ONAPGO is a wearable subcutaneous infusion ...